Another metric of excellence - with none other than @ppisters as co-author! 25y of @MDAndersonNews neoadjuvant Rx & surgical experience in #PancreaticCancer & median survivals (43 months & growing) that vastly outpaces national numbers. https:
CC: @NirajGusani @EUPancreas @worldjsurg Here's the @MDAndersonNews experience https://t.co/PE5ivstiyn https://t.co/Im7vgHTOen #SurgOnc https://t.co/yqKfvvf9xS
Tumori Pancreas Resecabili: tasso di sopravvivenza > 5anni nel 30% casi https://t.co/ZwvKfRX3Lg , https://t.co/HjGCFMfJGe #tumorepancreas https://t.co/ykdT6kbqAQ
RT @Aiims1742: 5y survival of resected #PancreaticCancer pts is ~30% https://t.co/Vsds3e6MPM (@VirginiaMason) At @MDAndersonNews https://…
RT @Aiims1742: Bottom line 5y survival rates of 9% for ALL #PancreaticCancer can be > tripled if > patients diagnosed at resectable stage…
RT @Aiims1742: Bottom line 5y survival rates of 9% for ALL #PancreaticCancer can be > tripled if > patients diagnosed at resectable stage…
RT @Aiims1742: 5y survival of resected #PancreaticCancer pts is ~30% https://t.co/Vsds3e6MPM (@VirginiaMason) At @MDAndersonNews https://…
RT @Aiims1742: Bottom line 5y survival rates of 9% for ALL #PancreaticCancer can be > tripled if > patients diagnosed at resectable stage…
RT @Aiims1742: 5y survival of resected #PancreaticCancer pts is ~30% https://t.co/Vsds3e6MPM (@VirginiaMason) At @MDAndersonNews https://…
RT @Aiims1742: Bottom line 5y survival rates of 9% for ALL #PancreaticCancer can be > tripled if > patients diagnosed at resectable stage…
RT @Aiims1742: Bottom line 5y survival rates of 9% for ALL #PancreaticCancer can be > tripled if > patients diagnosed at resectable stage…
Bottom line 5y survival rates of 9% for ALL #PancreaticCancer can be > tripled if > patients diagnosed at resectable stage #EarlyDetection https://t.co/XT2XumNo6w
5y survival of resected #PancreaticCancer pts is ~30% https://t.co/Vsds3e6MPM (@VirginiaMason) At @MDAndersonNews https://t.co/u120KF7EWp
RT @Aiims1742: ICYMI: @MDAndersonNews team shows neoadjuvant Rx & resection in #PancreaticCancer = 43 months OS https://t.co/ZdhtwZdKTR Be…
RT @Aiims1742: ICYMI: @MDAndersonNews team shows neoadjuvant Rx & resection in #PancreaticCancer = 43 months OS https://t.co/ZdhtwZdKTR Be…
RT @Aiims1742: ICYMI: @MDAndersonNews team shows neoadjuvant Rx & resection in #PancreaticCancer = 43 months OS https://t.co/ZdhtwZdKTR Be…
ICYMI: @MDAndersonNews team shows neoadjuvant Rx & resection in #PancreaticCancer = 43 months OS https://t.co/ZdhtwZdKTR Better than ever! https://t.co/f6y7mAh0vW
RT @Aiims1742: A significant advance from @MDAndersonNews in #PancreaticCancer -> successful preop Rx + resection = >43 months OS https://…
RT @Aiims1742: A significant advance from @MDAndersonNews in #PancreaticCancer -> successful preop Rx + resection = >43 months OS https://…
Now we need more patients diagnosed at resectable stage & improve adjuvant options to increase that OS even further in #PancreaticCancer https://t.co/opFK2zopjn
A significant advance from @MDAndersonNews in #PancreaticCancer -> successful preop Rx + resection = >43 months OS https://t.co/tD0A6P5pvb